Navigation Links
Harvest Technologies Corporation Granted CE Mark for Expanded Clinical Indication for Treatment of No-Option Critical Limb Ischemia
Date:11/19/2012

o compelling that we committed to and are currently enrolling patients in a US FDA pivotal trial."  

Harvest Technologies is the leading Cellular Therapy global manufacturer that develops point-of-care products to process and concentrate multiple biologics.  These include high-density platelet rich plasma (APC), bone marrow aspirate concentrate (BMAC®) and adipose tissue.  The company is headquartered in Plymouth, Massachusetts.  It is one of several subsidiaries of Terumo Corporation of Japan that is focused in cellular therapies and biologics.  For more information, visit www.harvesttech.com.

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use.

Harvest Technologies Corporation
Plymouth, MA  02360
(877) 842-7837

Harvest, SmartPReP and BMAC are registered trademarks of Harvest Technologies Corporation.  Terumo® is a registered trademark of Terumo Corporation.


'/>"/>
SOURCE Harvest Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Harvest Technologies Corporation reicht Patentverletzungsklage gegen ThermoGenesis Corporation ein
2. Harvest Technologies Corporation Files Patent Infringement Complaint against ThermoGenesis Corporation
3. Innovative Hematology and Flow Cytometry Technologies and Emerging Markets
4. Acuo Technologies Selected in Department of Defense Award to Deliver Vendor Neutral Archive for U.S. Army and U.S. Navy Medical Commands
5. Medisafe 1 Technologies Signs the $7MM Perpetual License Agreement
6. TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
7. Filtrona Porous Technologies präsentiert neue medizinische Schäume und einzigartige Faserprodukte für saubere Arbeitsumgebungen auf MEDICA / COMPAMED-Messe
8. Beyond Lucid Technologies Receives Funding From Dalmore Investments
9. Filtrona Porous Technologies Introduces New Medical-Grade Foams And Unique Fiber Products For Clean Environments At MEDICA / COMPAMED Trade Fair
10. Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
11. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... subsidiary, BreedIT Ltd., the exclusive worldwide distributor of highly ... announced that on January 7, 2014, the Company,s board ... Ben-Zion Weiner as its new member of ... Weiner held executive positions with Teva Pharmaceutical Industries Ltd ...
(Date:1/15/2014)... -- MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ... than 10 bps, yet are surprisingly capable in their ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 /PRNewswire/ ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ... the market as insulin delivery systems especially ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... ANGELES, Sept. 30 Actresses and mother-daughter pair Blythe Danner ... Entertainment Industry Foundation (EIF) public service announcement that celebrates the ... of PSAs that all major broadcast networks - ABC, CBS, FOX ... EIF,s iParticipate national initiative to promote service ...
... 30 According to a new,market research report, ,Neurostimulation ... for,neurostimulation products is expected to be worth $3.6 billion ... driven by the multiple treatment,applications of neurostimulation products, and ... Browse 48 market data tables and ...
... Sept. 30 On Tuesday, September 22, 2009, ... largest co-payment assistance organizations, hosted a panel discussion to ... underinsured and the related challenges of reducing financial barriers ... ) , Held at the National Press Club ...
... , SUNNYVALE, Calif., Sept. 30 Palo Alto Networks(TM), the ... selected to present at the Computer Forensics Show 2009, taking ... Julie Starr, a distinguished engineer at Palo Alto Networks, will ... and Control" in the IT Security Track on Oct. 6. ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... (bupropion SR/zonisamide SR), the Company,s second late stage investigational ... primary efficacy endpoint by demonstrating statistically significantly greater weight ... placebo. The Company plans to meet with the ...
... CITY, Calif., Sept. 30 Genomic Health, Inc. ... Health,s Chief Operating Officer and Chief Financial Officer, will present ... City, on Tuesday, October 6 at 9:30 a.m. ET. ... the presentation, visit the Investor Relations section of Genomic Health,s ...
Cached Medicine News:Health News:Blythe Danner and Gwyneth Paltrow Ask Americans to Volunteer for Healthier Life in New Public Service Announcement 2Health News:Blythe Danner and Gwyneth Paltrow Ask Americans to Volunteer for Healthier Life in New Public Service Announcement 3Health News:MarketsandMarkets: Global Neurostimulation Market Worth US$10.2 Billion by 2014 2Health News:MarketsandMarkets: Global Neurostimulation Market Worth US$10.2 Billion by 2014 3Health News:HealthWell Foundation(R) Gathers Leading Health Care Stakeholders to Discuss Crisis of the Underinsured 2Health News:HealthWell Foundation(R) Gathers Leading Health Care Stakeholders to Discuss Crisis of the Underinsured 3Health News:Palo Alto Networks to Present at the Computer Forensics Show 2009 2Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 2Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 3Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 4Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 5Health News:Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 6
... Medtronic has been a key participant ... for more than a decade. Previous Medtronic ... for concentrated platelets, as well as to ... for producing platelet-rich plasma (PRP) for a ...
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
... Biliary Self-Expanding Stent System combines low-profile, high radial ... .018" guide wire compatible stent system provides 6F ... diameters (5.0 - 10.0 mm). Now, with longer ... in five stent lengths (28, 38, 56, 80 ...
... Supreme and Response catheters comprise ... catheters available for electrophysiology procedures. Their ... provide for superior torque response with ... multiple curves and French sizes, Supreme ...
Medicine Products: